Skip to main content
Last Updated
In the Matter of Watson Pharmaceuticals Inc., Actavis Inc., Actavis Pharma Holding 4 ehf., and Actavis S..r.l.
FTC Matter/File Number
Docket Number
Enforcement Type
Part 2 Consents

Case Summary

The FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive. The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD).

There is a related federal proceeding and two related administrative proceedings:

Case Timeline